{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"64.4","upperLimit":"81.9","value":"73.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"107"}],"units":"Participants"}],"description":"The objective response rate was defined as the number of participants with a confirmed best response of morphologic complete remission, morphologic complete remission with partial recovery of peripheral blood counts, or morphologic partial remission by pure pathologic response (PPR) criteria. The PPR criteria are a modification of the mIWG-MRT-ECNM criteria that define deep responses where direct measure of the disease burden determined the response and focus on objective changes (bone marrow mast cell burden, serum tryptase, and complete blood count).","dispersionType":"95% Confidence Interval","groups":[{"description":"Avapritinib was administered once daily as an immediate-release tablet, orally, in 28-day cycles.","id":"OG000","title":"Avapritinib"}],"paramType":"NUMBER","populationDescription":"Pure Pathologic Response-evaluable Population: all participants who received ≥1 dose of avapritinib and had 1 of the following conditions: ≥2 complete postbaseline bone marrow assessments and had been on study for ≥6 cycles; had an end of study visit.","reportingStatus":"POSTED","timeFrame":"Baseline through Month 65","title":"Objective Response Rate","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}